# US 2019/0240319 A1 · Biochemically stabilized hiv-1 env trimer vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240319 A1
- Document ID: US20190240319A1
- Status: Published application
- Kind: A1
- Application number: 16/385,438
- Filed: 2019-04-16
- Published: 2019-08-08
- Earliest claimed: 2008-10-10
- Assignees: Beth Israel Deaconess Medical Center, Inc.; Children's Medical Center Corporation
- Applicants: Beth Israel Deaconess Medical Center, Inc.; Children's Medical Center Corporation
- Inventors: Stephen C. HARRISON; Bing CHEN; Dan H. BAROUCH; Joseph P. NKOLOLA; Michael Scott SEAMAN
- Web page: https://patentgrep.com/patent/US20190240319A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/575: {humoral response}
- C12N 2740/16051: Methods of production or purification of viral material
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

An immunogenic composition comprising:
an isolated gp140 polypeptide trimer, wherein the trimer comprises three identical polypeptide sequences, each polypeptide sequence comprising a gp140 polypeptide sequence that is at least 98% identical to residues 30-716 of SEQ ID NO:1.

### Claim 22 (depends on 21)

The immunogenic composition of claim 21, wherein the immunogenic composition elicits production of antibodies against HIV-1 after injection into a subject.

### Claim 23 (depends on 22)

The immunogenic composition of claim 22, wherein the antibodies comprise anti-HIV-1 clade A antibodies.

### Claim 24 (depends on 21)

The immunogenic composition of claim 21, wherein the gp140 polypeptide sequence includes an oligomerization domain.

### Claim 25 (depends on 24)

The immunogenic composition of claim 24, wherein the oligomerization domain is a T4 fibritin trimerization domain.

### Claim 26 (depends on 21)

The immunogenic composition of claim 21, wherein the gp140 polypeptide sequence that is at least 98% identical to residues 30-716 of SEQ ID NO: 1 includes SEQ ID NO:7 and/or SEQ ID NO:5.

### Claim 27 (depends on 21)

The immunogenic composition of claim 21, wherein the polypeptide sequence comprising a gp140 polypeptide sequence is at least 99% identical to residues 30-716 of SEQ ID NO:1.

### Claim 28 (depends on 21)

The immunogenic composition of claim 21, further comprising an adjuvant.

### Claim 29

An isolated gp140 polypeptide trimer, wherein the gp140 polypeptide trimer comprises three identical gp140 polypeptides comprising an amino acid sequence at least 98% identical to residues 30-716 of SEQ ID NO:1.

### Claim 30 (depends on 29)

The gp140 polypeptide trimer of claim 29, wherein the gp140 polypeptide trimer elicits production of antibodies against HIV-1 after injection into a subject.

### Claim 31 (depends on 30)

The gp140 polypeptide trimer of claim 30, wherein the antibodies comprise anti-HIV-1 clade A antibodies.

### Claim 32 (depends on 29)

The gp140 polypeptide trimer of claim 29, wherein the gp140 polypeptide sequence includes an oligomerization domain.

### Claim 33 (depends on 32)

The gp140 polypeptide trimer of claim 32, wherein the oligomerization domain is a T4 fibritin trimerization domain.

### Claim 34 (depends on 29)

The gp140 polypeptide trimer of claim 29, wherein the gp140 polypeptide sequence that is at least 98% identical to residues 30-716 of SEQ ID NO: 1 includes SEQ ID NO:7 and/or SEQ ID NO:5.

### Claim 35 (depends on 21)

A method of treating or inhibiting an HIV-1-mediated activity in a subject infected with HIV-1 comprising:
a. contacting a subject infected with HIV-1 with the immunogenic composition of claim 21; and
b. producing anti-HIV-1 antibodies in the subject to treat or inhibit the HIV-1 mediated activity in the subject infected with HIV-1.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anti-HIV-1 antibodies are selected from one or more of anti-HIV-1 clade A antibodies, anti-HIV-1 clade B antibodies, and anti-HIV-1 clade C antibodies.

### Claim 37 (depends on 35)

The method of claim 35, wherein the HIV-1 mediated activity is viral spread.

### Claim 38 (depends on 21)

A method of inducing an immune response against HIV-1 in a subject, the method comprising:
a. contacting a subject with the immunogenic composition of claim 21; and
b. inducing an immune response against HIV-1 in the subject.

### Claim 39 (depends on 38)

The method of claim 38, wherein the subject is not infected with HIV-1 at the moment of administration of the immunogenic composition.

### Claim 40

An isolated nucleic acid molecule encoding at least one gp140 polypeptide, wherein said gp140 polypeptide comprises an amino acid sequence at least 98% identical to residues 30-716 of SEQ ID NO: 1.
